<?xml version='1.0' encoding='utf-8'?>
<document id="31713224"><sentence text="Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling." /><sentence text="Elagolix is approved for the management of moderate-to-severe pain associated with endometriosis" /><sentence text=" The aim of this analysis was to develop a physiologically based pharmacokinetic (PBPK) model that describes the enzyme-transporter interplay involved in the disposition of elagolix and to predict the magnitude of drug-drug interaction (DDI) potential of elagolix as an inhibitor of P-glycoprotein (P-gp) and inducer of cytochrome P450 (CYP) 3A4" /><sentence text="" /><sentence text="A PBPK model (SimCYP® version 15" /><sentence text="0" /><sentence text="86" /><sentence text="0) was developed using elagolix data from in vitro, clinical PK and DDI studies" /><sentence text=" Data from DDI studies were used to quantify contributions of the uptake transporter organic anion transporting polypeptide (OATP) 1B1 and CYP3A4 in the disposition of elagolix, and to quantitatively assess the perpetrator potential of elagolix as a CYP3A4 inducer and P-gp inhibitor" /><sentence text="" /><sentence text="After accounting for the interplay between elagolix metabolism by CYP3A4 and uptake by OATP1B1, the model-predicted PK parameters of elagolix along with the DDI AUC∞ and Cmax ratios, were within 1" /><sentence text="5-fold of the observed data" /><sentence text=" Based on model simulations, elagolix 200 mg administered twice daily is a moderate inducer of CYP3A4 (approximately 56% reduction in midazolam AUC∞)" /><sentence text=" Simulations of elagolix 150 mg administered once daily with digoxin predicted an increase in digoxin Cmax and AUC∞ by 68% and 19%, respectively"><entity charOffset="61-68" id="DDI-PubMed.31713224.s14.e0" text="digoxin" /></sentence><sentence text="" /><sentence text="A PBPK model of elagolix was developed, verified, and applied to characterize the disposition interplay between CYP3A4 and OATP1B1, and to predict the DDI potential of elagolix as a perpetrator under dosing conditions that were not tested clinically" /><sentence text=" PBPK model-based predictions were used to support labeling language for DDI recommendations of elagolix" /><sentence text="" /></document>